CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the results of its antiviral drug molecular characterization study performed by the National Research Council (“NRC”). The results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with DehydraTECH. “This could preserve the ability of this drug delivery platform to qualify for accelerated regulatory filings with the Food and Drug Administration (‘FDA’) in the United States plus regulators elsewhere in the world,” reads a recent article. “The potential for more rapid market authorization of DehydraTECH provides the potential for cost savings to the health care…